Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
74 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014', provides an overview of the Complicated Intra-Abdominal Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Complicated Intra-Abdominal Infections Overview 7 Therapeutics Development 8 Pipeline Products for Complicated Intra-Abdominal Infections - Overview 8 Pipeline Products for Complicated Intra-Abdominal Infections - Comparative Analysis 9 Complicated Intra-Abdominal Infections - Therapeutics under Development by Companies 10 Complicated Intra-Abdominal Infections - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Complicated Intra-Abdominal Infections - Products under Development by Companies 15 Complicated Intra-Abdominal Infections - Companies Involved in Therapeutics Development 16 AstraZeneca PLC 16 Merck & Co., Inc. 17 Melinta Therapeutics, Inc 18 Cubist Pharmaceuticals, Inc. 19 MerLion Pharmaceuticals Pte Ltd 20 Nabriva Therapeutics AG 21 Atox Bio Inc. 22 Tetraphase Pharmaceuticals Inc. 23 Complicated Intra-Abdominal Infections - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 (ceftolozane + tazobactam) - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 eravacycline - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 (ceftazidime + avibactam) - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 delafloxacin - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 MK-7655 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AB-103 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules to Inhibit 50S RNA for Infections - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KBP-7072 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 finafloxacin - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Complicated Intra-Abdominal Infections - Recent Pipeline Updates 51 Complicated Intra-Abdominal Infections - Dormant Projects 62 Complicated Intra-Abdominal Infections - Discontinued Products 63 Complicated Intra-Abdominal Infections - Product Development Milestones 64 Featured News & Press Releases 64 Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 64 Mar 20, 2014: Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline 65 Dec 16, 2013: Cubist Announces Positive Top-Line Results from Phase 3 Trial of Ceftolozane/Tazobactam in Intra-Abdominal Infections 66 Sep 12, 2013: Ceftazidime/avibactam Combination Receives Qualified Infectious Disease Product (QIDP) Designation from FDA 68 Sep 04, 2013: Tetraphase to Present Data at ICAAC Supporting Its Lead Antibiotic Candidate Eravacycline's Effectiveness against Multi-drug Resistant Pathogens 68 Sep 03, 2013: Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections 69 Jul 15, 2013: FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate 70 May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 71 Jan 07, 2013: Cubist Pharma Provides Update On Infectious Disease Drug Candidate, Ceftolozane 71 Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 72 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 74 Disclaimer 74
List of Tables Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2014 8 Number of Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Complicated Intra-Abdominal Infections - Pipeline by AstraZeneca PLC, H2 2014 16 Complicated Intra-Abdominal Infections - Pipeline by Merck & Co., Inc., H2 2014 17 Complicated Intra-Abdominal Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 18 Complicated Intra-Abdominal Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19 Complicated Intra-Abdominal Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014 20 Complicated Intra-Abdominal Infections - Pipeline by Nabriva Therapeutics AG, H2 2014 21 Complicated Intra-Abdominal Infections - Pipeline by Atox Bio Inc., H2 2014 22 Complicated Intra-Abdominal Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Assessment by Combination Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Complicated Intra-Abdominal Infections Therapeutics - Recent Pipeline Updates, H2 2014 51 Complicated Intra-Abdominal Infections - Dormant Projects, H2 2014 62 Complicated Intra-Abdominal Infections - Discontinued Products, H2 2014 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.